Sanofi India third quarter results live broadcast: Sanofi India announced its third quarter results on November 7, 2024, with both revenue and profit declining significantly. The company’s revenue fell by 26.67% year-on-year, and its profits dropped significantly by 45.89% compared with the same period last year.
Compared with the previous quarter, Sanofi India’s revenue increased by 13.05% and its profit fell by 20.35%. This suggests a mixed performance, with some recovery on a quarter-on-quarter basis despite year-on-year declines.
The company’s selling expenses, general expenses and administrative expenses showed a positive trend, with a quarterly decrease of 5.81% and a decrease of 39.16% compared with the same period last year. The reduction in expenses may provide some relief amid declining revenue.
Operating income in the third quarter increased by 3.75% compared with the previous quarter, but still dropped significantly by 44.18% year-on-year. This points to challenges in maintaining profitability despite cost-cutting measures.
Earnings per share (EPS) also took a hit, at $In the third quarter, it was 35.69, a year-on-year decrease of 45.88%. This decline may worry investors as it reflects the overall profitability challenges facing the company.
Looking at stock performance, Sanofi India returned -3.48% over the past week. However, the company has returned 29.46% over the past six months and 29.96% year-to-date, suggesting resilience over the long term despite recent volatility.
As of November 8, 2024, Sanofi India’s market capitalization was $15,103.14 Crore and the 52-week trading range is $4,694.05 and $7,600. This range reflects the market’s fluctuating sentiment about the company’s performance.
Analyst sentiment appears cautiously optimistic, with two-thirds recommending a buy rating and one analyst assigning a strong buy rating. As of November 8, 2024, the consensus recommendation is “Strong Buy,” indicating the potential for recovery.
